NASDAQ: OMOutset Medical Inc Stock
$3.61+0.09 (+2.56%)
Updated May 17, 2024
OM Price
$3.61
Fair Value Price
N/A
Market Cap
$186.72M
52 Week Low
$1.92
52 Week High
$24.13
P/E
-1.07x
P/B
2x
P/S
0.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$125.08M
Earnings
-$168.77M
Gross Margin
24.6%
Operating Margin
-121.99%
Profit Margin
-134.9%
Debt to Equity
2.72
Operating Cash Flow
-$133M
Beta
1.53
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OM Overview
Outset Medical, Inc. offers the Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and cloud-connected software and connectivity capabilities used for dialysis care in acute and home settings. Formerly Home Dialysis Plus, Ltd., Outset Medical was incorporated in 2003 and is headquartered in San Jose, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OM is good value based on its book value relative to its share price (2x), compared to the US Medical Devices industry average (4x)
P/B vs Industry Valuation
OM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OM due diligence checks available for Premium users.
Be the first to know about important OM news, forecast changes, insider trades & much more!
OM News
Valuation
OM fair value
Fair Value of OM stock based on Discounted Cash Flow (DCF)
Price
$3.61
Fair Value
$3.30
Overvalued by
9.28%
OM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.07x
Industry
30.6x
Market
30.97x
OM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2x
Industry
4x
OM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OM's financial health
Profit margin
Revenue
$28.2M
Net Income
-$39.9M
Profit Margin
-141.8%
OM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$346.2M
Liabilities
$253.0M
Debt to equity
2.72
OM's short-term assets ($325.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OM's short-term assets ($325.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$45.9M
Investing
-$59.0M
Financing
$68.6M
OM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OM vs Medical Device Stocks
Outset Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.